RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TOT BIOPHARM International Co - Stock

TOT BIOPHARM International Co Debt 2024

TOT BIOPHARM International Co Debt

-5.95 CNY

Ticker

1875.HK

ISIN

HK0000545266

In 2024, TOT BIOPHARM International Co's total debt was -5.95 CNY, a -95.36% change from the -128.24 CNY total debt recorded in the previous year.

TOT BIOPHARM International Co Aktienanalyse

What does TOT BIOPHARM International Co do?

TOT BIOPHARM International Co Ltd is a global biotechnology company based in Hong Kong. It was founded in 2005 and has since become a major player in the biopharmaceutical industry. The company's goal is to contribute to the improvement of medical care through innovative research and development of biological drugs. TOT BIOPHARM's business activities include pharmaceutical development, clinical research, and production of biological drugs. It serves various sectors, including cancer, immunology, ophthalmology, and vaccines. TOT BIOPHARM is strongly committed to the development of biopharmaceuticals and aims to be a leader in this field. One important focus of TOT BIOPHARM is the research of cancer drugs. The company has several drugs in its oncology pipeline, including a treatment for lung cancer called "Ponatinib". Additionally, TOT BIOPHARM has introduced a range of immuno-oncology therapies that can be used to treat various types of cancer. In the field of immunology, TOT BIOPHARM has launched several drugs for the treatment of autoimmune diseases, including "Natalizumab" for multiple sclerosis. Another important immunotherapy developed by TOT BIOPHARM is "Eculizumab," which is used to treat two rare blood disorders. In ophthalmology, TOT BIOPHARM is developing a new drug for the treatment of wet age-related macular degeneration (AMD). The drug is being tested in a Phase III clinical trial and has the potential to become the first biopharmaceutical for the treatment of AMD. Furthermore, TOT BIOPHARM has also developed vaccines, including a vaccine against the Japanese encephalitis virus (JEV) and a vaccine against enterovirus 71 (EV71). Both vaccines have been approved in China and are in high demand. TOT BIOPHARM's business model focuses on building a pipeline of innovative biopharmaceuticals that meet the needs of patients. The company operates a comprehensive research and development infrastructure that helps discover and develop new drug candidates. TOT BIOPHARM collaborates with universities, government agencies, and other business partners to accelerate its research and development and strengthen its market position. In addition, TOT BIOPHARM has a strong presence in the Chinese market for biopharmaceuticals. The company has a state-approved clinical research facility with over 1,000 employees in China and collaborates with leading Chinese hospitals and specialty clinics. This has given TOT BIOPHARM a preferred position in the Chinese market for biopharmaceuticals, and the company aims to expand its presence in other markets worldwide. Overall, TOT BIOPHARM International Co Ltd has built an impressive portfolio of biopharmaceuticals in recent years and is expected to continue to play a significant role in the biopharmaceutical industry. With a clear focus on research and development and a growing market position in China and other countries, the company is well-positioned to expand its business activities and strengthen its presence in the global market. TOT BIOPHARM International Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding TOT BIOPHARM International Co's Debt Structure

TOT BIOPHARM International Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing TOT BIOPHARM International Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to TOT BIOPHARM International Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in TOT BIOPHARM International Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about TOT BIOPHARM International Co Stock

What is the debt of TOT BIOPHARM International Co this year?

TOT BIOPHARM International Co has a debt level of -5.95 CNY this year.

What was the debt of TOT BIOPHARM International Co compared to the previous year?

The debt of TOT BIOPHARM International Co has increased by -95.36% compared to the previous year dropped.

What are the consequences of high debt for investors in TOT BIOPHARM International Co?

High debt can pose a risk for investors of TOT BIOPHARM International Co, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of TOT BIOPHARM International Co?

Low debt means that TOT BIOPHARM International Co has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from TOT BIOPHARM International Co affect the company?

An increase in debt of TOT BIOPHARM International Co can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of TOT BIOPHARM International Co affect the company?

A reduction in debt of TOT BIOPHARM International Co can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of TOT BIOPHARM International Co?

Some factors that can influence the debt of TOT BIOPHARM International Co include investments, acquisitions, operating costs, and revenue development.

Why are the debts of TOT BIOPHARM International Co so important for investors?

The debts of TOT BIOPHARM International Co are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can TOT BIOPHARM International Co take to change the debt?

To change the debt, TOT BIOPHARM International Co can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does TOT BIOPHARM International Co pay?

Over the past 12 months, TOT BIOPHARM International Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TOT BIOPHARM International Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of TOT BIOPHARM International Co?

The current dividend yield of TOT BIOPHARM International Co is .

When does TOT BIOPHARM International Co pay dividends?

TOT BIOPHARM International Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TOT BIOPHARM International Co?

TOT BIOPHARM International Co paid dividends every year for the past 0 years.

What is the dividend of TOT BIOPHARM International Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is TOT BIOPHARM International Co located?

TOT BIOPHARM International Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von TOT BIOPHARM International Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TOT BIOPHARM International Co from 7/1/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did TOT BIOPHARM International Co pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of TOT BIOPHARM International Co in the year 2023?

In the year 2023, TOT BIOPHARM International Co distributed 0 CNY as dividends.

In which currency does TOT BIOPHARM International Co pay out the dividend?

The dividends of TOT BIOPHARM International Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von TOT BIOPHARM International Co

Our stock analysis for TOT BIOPHARM International Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TOT BIOPHARM International Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.